Target Price | $100.98 |
Price | $84.71 |
Potential | 19.21% |
Number of Estimates | 27 |
27 Analysts have issued a price target Merck & Co. 2026 . The average Merck & Co. target price is $100.98. This is 19.21% higher than the current stock price. The highest price target is $148.05 74.77% , the lowest is $82.82 2.23% . | |
A rating was issued by 33 analysts: 19 Analysts recommend Merck & Co. to buy, 14 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck & Co. stock has an average upside potential 2026 of 19.21% . Most analysts recommend the Merck & Co. stock at Purchase. |
27 Analysts have issued a sales forecast Merck & Co. 2025 . The average Merck & Co. sales estimate is $65.4b . This is 2.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $68.7b 7.93% , the lowest is $62.8b 1.26% .
This results in the following potential growth metrics:
2024 | $64.2b | 6.74% |
---|---|---|
2025 | $65.4b | 1.91% |
2026 | $68.6b | 4.97% |
2027 | $72.7b | 5.85% |
2028 | $73.5b | 1.20% |
2029 | $70.9b | 3.61% |
2030 | $68.2b | 3.77% |
2031 | $66.1b | 3.03% |
2032 | $65.1b | 1.58% |
14 Analysts have issued an Merck & Co. EBITDA forecast 2025. The average Merck & Co. EBITDA estimate is $30.3b . This is 6.57% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $33.8b 18.75% , the lowest is $27.5b 3.54% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $28.8b | 15.05% |
---|---|---|
2025 | $30.3b | 5.36% |
2026 | $32.9b | 8.43% |
2027 | $35.5b | 7.92% |
2028 | $37.6b | 5.90% |
2029 | $36.1b | 4.05% |
2030 | $30.5b | 15.36% |
2031 | $28.5b | 6.65% |
2032 | $27.1b | 4.95% |
2024 | 44.87% | 7.78% |
---|---|---|
2025 | 46.39% | 3.38% |
2026 | 47.92% | 3.30% |
2027 | 48.85% | 1.94% |
2028 | 51.13% | 4.67% |
2029 | 50.89% | 0.47% |
2030 | 44.77% | 12.03% |
2031 | 43.09% | 3.75% |
2032 | 41.62% | 3.41% |
27 Merck & Co. Analysts have issued a net profit forecast 2025. The average Merck & Co. net profit estimate is $22.5b . This is 37.39% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $23.8b 44.98% , the lowest is $21.6b 31.40% .
This results in the following potential growth metrics and future Net Margins:
2024 | $17.1b | 4,589.59% |
---|---|---|
2025 | $22.5b | 31.68% |
2026 | $24.3b | 7.81% |
2027 | $27.0b | 11.14% |
2028 | $26.3b | 2.70% |
2029 | $24.8b | 5.46% |
2030 | $22.6b | 9.22% |
2031 | $21.3b | 5.49% |
2032 | $20.7b | 2.82% |
2024 | 26.68% | 4,293.38% |
---|---|---|
2025 | 34.47% | 29.22% |
2026 | 35.40% | 2.70% |
2027 | 37.17% | 5.00% |
2028 | 35.74% | 3.85% |
2029 | 35.05% | 1.93% |
2030 | 33.07% | 5.65% |
2031 | 32.23% | 2.54% |
2032 | 31.82% | 1.27% |
27 Analysts have issued a Merck & Co. forecast for earnings per share. The average Merck & Co. EPS is $9.00 . This is 38.04% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.50 45.71% , the lowest is $8.61 32.06% .
This results in the following potential growth metrics and future valuations:
2024 | $6.74 | 4,714.29% |
---|---|---|
2025 | $9.00 | 33.53% |
2026 | $9.71 | 7.89% |
2027 | $10.79 | 11.12% |
2028 | $10.50 | 2.69% |
2029 | $9.93 | 5.43% |
2030 | $9.01 | 9.26% |
2031 | $8.52 | 5.44% |
2032 | $8.28 | 2.82% |
Current | 12.99 | 40.99% |
---|---|---|
2025 | 9.41 | 27.57% |
2026 | 8.73 | 7.23% |
2027 | 7.85 | 10.08% |
2028 | 8.07 | 2.80% |
2029 | 8.53 | 5.70% |
2030 | 9.40 | 10.20% |
2031 | 9.95 | 5.85% |
2032 | 10.24 | 2.91% |
Based on analysts' sales estimates for 2025, the Merck & Co. stock is valued at an EV/Sales of 3.65 and an P/S ratio of 3.24 .
This results in the following potential growth metrics and future valuations:
Current | 3.75 | 28.30% |
---|---|---|
2025 | 3.65 | 2.80% |
2026 | 3.47 | 4.74% |
2027 | 3.28 | 5.52% |
2028 | 3.24 | 1.19% |
2029 | 3.36 | 3.74% |
2030 | 3.49 | 3.92% |
2031 | 3.60 | 3.12% |
2032 | 3.66 | 1.60% |
Current | 3.33 | 30.79% |
---|---|---|
2025 | 3.24 | 2.72% |
2026 | 3.08 | 4.73% |
2027 | 2.91 | 5.53% |
2028 | 2.88 | 1.18% |
2029 | 2.99 | 3.75% |
2030 | 3.10 | 3.92% |
2031 | 3.20 | 3.13% |
2032 | 3.25 | 1.60% |
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 30 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 10 2025 |
Citigroup |
Buy
➜
Neutral
|
Downgrade | May 14 2025 |
Cantor Fitzgerald |
➜
Neutral
|
Initiated | Apr 22 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Apr 17 2025 |
Deutsche Bank |
Buy
➜
Hold
|
Downgrade | Feb 18 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Feb 12 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Jul 30 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 10 2025 |
Downgrade
Citigroup:
Buy
➜
Neutral
|
May 14 2025 |
Initiated
Cantor Fitzgerald:
➜
Neutral
|
Apr 22 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Apr 17 2025 |
Downgrade
Deutsche Bank:
Buy
➜
Hold
|
Feb 18 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Feb 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.